{
    "Trade/Device Name(s)": [
        "LYHER\u00ae Oral fluid Multi-Drug Test Kit (Cube)"
    ],
    "Submitter Information": "Hangzhou Laihe Biotech Co., Ltd.",
    "510(k) Number": "K240287",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171403"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJC",
        "DIO",
        "DJG",
        "DKZ",
        "LCM",
        "LDJ"
    ],
    "Summary Letter Date": "January 24, 2025",
    "Summary Letter Received Date": "February 6, 2025",
    "Submission Date": "March 6, 2025",
    "Regulation Number(s)": [
        "21 CFR 862.3610",
        "21 CFR 862.3250",
        "21 CFR 862.3650",
        "21 CFR 862.3100",
        "21 CFR 862.3870"
    ],
    "Regulation Name(s)": [
        "Methamphetamine Test System",
        "Cocaine Test System",
        "Opiate Test System",
        "Amphetamine Test System",
        "Cannabinoid Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "d-Amphetamine",
        "d-Methamphetamine",
        "Benzoylecgonine",
        "Morphine",
        "Phencyclidine",
        "Delta-9-Tetrahydrocannabinol"
    ],
    "Specimen Type(s)": [
        "Oral fluid"
    ],
    "Specimen Container(s)": [
        "Oral fluid collection swab",
        "Cube device"
    ],
    "Instrument(s)/Platform(s)": [
        "Cube device"
    ],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay",
        "Immunochromatographic assay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunochemistry"
    ],
    "Submission Type(s)": [
        "Kit",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for LYHER Oral fluid Multi-Drug Test Kit (Cube) using lateral flow immunoassay for qualitative detection of six drugs of abuse in human oral fluid.",
    "Indications for Use Summary": "Rapid lateral flow immunoassay for qualitative detection of d-Amphetamine, d-Methamphetamine, Benzoylecgonine, Morphine, Phencyclidine, and Delta-9-Tetrahydrocannabinol in human oral fluid, providing only preliminary results.",
    "fda_folder": "Toxicology"
}